Prof. Harvey Lodish

Professor Lodish is a renowned biologist who is a founding member of the Whitehead Institute for Biomedical Research and serves as a professor of biology and biological engineering at MIT. He is a member of the National Academy of Sciences and is a foreign associate member of the European Molecular Biology Organization. He is a fellow of several prestigious organizations, including the American Association for the Advancement of Science, the American Academy of Arts and Sciences, and the American Academy of Microbiology.

He chairs the Board of Trustees Research Committee at Boston Children's Hospital and was the Founding Chair of the Scientific Advisory Board of the Massachusetts Life Sciences Center from 2008 to 2016, where he was responsible for overseeing the state's $1 billion investment in the life sciences.

His lab, starting in 1973, has focused on the biogenesis, structure, and function of glycoproteins and has made significant contributions to the fields of red blood cell development and therapeutics, long non-coding RNAs, and adipocyte biology. He previously co-founded Rubius Therapeutics, which uses gene-modified red blood cells as a vehicle for delivering novel therapies and diagnostic imaging probes.

With extensive experience in the biotechnology industry, Prof. Lodish has co-founded several companies, including BIA, Genzyme, and Arris Pharmaceuticals (now Axys), and has served on the scientific advisory boards of AstraZeneca, Genset SA, Dyax Corporation, and others.